# ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis

> **NCT02517528** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 104 (actual)

## Conditions studied

- Chronic Hepatitis C Virus (HCV)

## Interventions

- **DRUG:** ABT-450/r/ABT-267
- **DRUG:** ABT-333
- **DRUG:** ribavirin

## Key facts

- **NCT ID:** NCT02517528
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-20
- **Primary completion:** 2016-09-29
- **Final completion:** 2017-03-16
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2018-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02517528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02517528, "ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02517528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*